As these angiogenic pathways were presumably not enough suppressed by sunitinib – at least at the doses used in this trial (Feldman et al, 2009), we searched for a more potent and specific VEGFR-inhibitor, which may show a more pronounced antiangiogenic effect in GCT. This evidence concerns the gene KDR and granular cell tumor.